December 22, 2024 - 14:43

Proprietary mutual funds may seem appealing due to their personalized approach and tailored investment strategies, but they come with significant drawbacks that investors should carefully consider before making any commitments. These funds are often managed by financial institutions that have a vested interest in promoting their own products, which can lead to conflicts of interest.
Investors may find themselves facing higher fees and expenses compared to non-proprietary options. Additionally, the limited range of investment choices can restrict diversification, potentially increasing risk. The performance of proprietary funds may also be influenced by the institution’s marketing strategies rather than pure investment merit, making it challenging for investors to gauge true performance.
Before investing in proprietary mutual funds, individuals should conduct thorough research and weigh the potential benefits against the inherent risks. Consulting with a financial advisor can provide valuable insights and help investors make informed decisions tailored to their financial goals.
May 30, 2026 - 02:29
Piper Sandler Reaffirms Overweight on Corebridge Financial (CRBG) Despite Lower Price TargetPiper Sandler has reaffirmed its Overweight rating on Corebridge Financial (CRBG) even as it lowered the price target for the stock. The firm reduced its target to $31 from $35, citing recent stock...
May 29, 2026 - 19:46
AHF Reveals Top 50 Developers and Owners in Latest IssueThe latest issue of Affordable Housing Finance has released its annual ranking of the top 50 developers and owners in the affordable housing sector. The list highlights the companies that have...
May 29, 2026 - 04:11
Americans Are Falling Behind on Their $1.25 Trillion Credit-Card BillSoaring interest rates and stubborn inflation have pushed credit card delinquencies to their highest level since the financial crisis of 2008. According to recent data, the total balance Americans...
May 28, 2026 - 17:58
OSE Immunotherapeutics to Implement a Flexible Bridge Equity FinancingFrench biotech firm OSE Immunotherapeutics has announced a flexible bridge equity financing arrangement, marking the first step in a broader global financing strategy. The company is currently...